Suppr超能文献

晚期丙型肝炎病毒感染中的凝血酶激活与肝脏炎症

Thrombin activation and liver inflammation in advanced hepatitis C virus infection.

作者信息

González-Reimers Emilio, Quintero-Platt Geraldine, Martín-González Candelaria, Pérez-Hernández Onán, Romero-Acevedo Lucía, Santolaria-Fernández Francisco

机构信息

Emilio González-Reimers, Geraldine Quintero-Platt, Candelaria Martín-González, Onán Pérez-Hernández, Lucía Romero-Acevedo, Francisco Santolaria-Fernández, Servicio de Medicina Interna, Hospital Universitario de Canarias, Universidad de La Laguna, Tenerife, 38320 Canary Islands, Spain.

出版信息

World J Gastroenterol. 2016 May 14;22(18):4427-37. doi: 10.3748/wjg.v22.i18.4427.

Abstract

Hepatitis C virus (HCV) infection is associated with increased thrombotic risk. Several mechanisms are involved including direct endothelial damage by the HCV virus, with activation of tissue factor, altered fibrinolysis and increased platelet aggregation and activation. In advanced stages, chronic HCV infection may evolve to liver cirrhosis, a condition in which alterations in the portal microcirculation may also ultimately lead to thrombin activation, platelet aggregation, and clot formation. Therefore in advanced HCV liver disease there is an increased prevalence of thrombotic phenomena in portal vein radicles. Increased thrombin formation may activate hepatic stellate cells and promote liver fibrosis. In addition, ischemic changes derived from vascular occlusion by microthrombi favor the so called parenchymal extinction, a process that promotes collapse of hepatocytes and the formation of gross fibrous tracts. These reasons may explain why advanced HCV infection may evolve more rapidly to end-stage liver disease than other forms of cirrhosis.

摘要

丙型肝炎病毒(HCV)感染与血栓形成风险增加有关。涉及多种机制,包括HCV病毒对内皮细胞的直接损伤,伴有组织因子激活、纤维蛋白溶解改变以及血小板聚集和激活增加。在晚期,慢性HCV感染可能发展为肝硬化,在这种情况下,门静脉微循环的改变最终也可能导致凝血酶激活、血小板聚集和血栓形成。因此,在晚期HCV肝病中,门静脉分支血栓形成现象的发生率增加。凝血酶形成增加可能激活肝星状细胞并促进肝纤维化。此外,微血栓导致的血管闭塞引起的缺血性改变有利于所谓的实质细胞消亡,这一过程促进肝细胞塌陷和粗大纤维束的形成。这些原因可能解释了为什么晚期HCV感染比其他形式的肝硬化更易迅速发展为终末期肝病。

相似文献

1
Thrombin activation and liver inflammation in advanced hepatitis C virus infection.
World J Gastroenterol. 2016 May 14;22(18):4427-37. doi: 10.3748/wjg.v22.i18.4427.
3
Parenchymal extinction: coagulation and hepatic fibrogenesis.
Clin Liver Dis. 2009 Feb;13(1):117-126. doi: 10.1016/j.cld.2008.09.013.
4
Serum omentin and vaspin levels in cirrhotic patients with and without portal vein thrombosis.
World J Gastroenterol. 2017 Apr 14;23(14):2613-2624. doi: 10.3748/wjg.v23.i14.2613.
6
Coagulation and fibrosis in chronic liver disease.
Gut. 2008 Dec;57(12):1722-7. doi: 10.1136/gut.2008.150748.
7
Pathological process of liver sinusoidal endothelial cells in liver diseases.
World J Gastroenterol. 2017 Nov 21;23(43):7666-7677. doi: 10.3748/wjg.v23.i43.7666.
8
Toll-like receptor-4 expression by hepatic progenitor cells and biliary epithelial cells in HCV-related chronic liver disease.
Mod Pathol. 2012 Apr;25(4):576-89. doi: 10.1038/modpathol.2011.197. Epub 2011 Dec 16.
10
Mechanisms Underlying Hepatitis C Virus-Associated Hepatic Fibrosis.
Cells. 2019 Oct 14;8(10):1249. doi: 10.3390/cells8101249.

引用本文的文献

1
Mechanistic Insights into the Role of MCP-1 in Diverse Liver Pathological Conditions: A Recent Update.
Curr Pharm Des. 2025 Mar 3;31(15):1167-1179. doi: 10.2174/0113816128332969241120030733.
2
Correlation Between Thrombin Generation and Hepatic Fibrosis in Chronic Liver Diseases.
Cureus. 2024 Oct 13;16(10):e71376. doi: 10.7759/cureus.71376. eCollection 2024 Oct.
5
Interaction between coagulation and inflammatory system in liver disease: re-focus on hematological markers.
Biomark Med. 2024;18(19):813-822. doi: 10.1080/17520363.2024.2395245. Epub 2024 Sep 4.
6
Hepatic microcirculatory disturbance in liver diseases: intervention with traditional Chinese medicine.
Front Pharmacol. 2024 Jul 23;15:1399598. doi: 10.3389/fphar.2024.1399598. eCollection 2024.
7
The association between hepatitis C virus infection status and blood pressure in adults in the United States: NHANES 1999-2012.
Front Cell Infect Microbiol. 2024 Jun 4;14:1401323. doi: 10.3389/fcimb.2024.1401323. eCollection 2024.
8
A Review on The Pathogenesis of Cardiovascular Disease of Viruses Infection.
Viruses. 2024 Feb 27;16(3):365. doi: 10.3390/v16030365.
10
A Machine Learning Framework for Assessing the Risk of Venous Thromboembolism in Patients Undergoing Hip or Knee Replacement.
J Healthc Inform Res. 2022 Oct 25;6(4):423-441. doi: 10.1007/s41666-022-00121-2. eCollection 2022 Dec.

本文引用的文献

1
The M358R variant of α(1)-proteinase inhibitor inhibits coagulation factor VIIa.
Biochem Biophys Res Commun. 2016 Feb 12;470(3):710-713. doi: 10.1016/j.bbrc.2016.01.069. Epub 2016 Jan 13.
2
Antithrombin: anti-inflammatory properties and clinical applications.
Thromb Haemost. 2016 Apr;115(4):712-28. doi: 10.1160/TH15-08-0687. Epub 2015 Dec 17.
3
Tissue Factor Pathway Inhibitor: Multiple Anticoagulant Activities for a Single Protein.
Arterioscler Thromb Vasc Biol. 2016 Jan;36(1):9-14. doi: 10.1161/ATVBAHA.115.305996. Epub 2015 Nov 24.
5
Thrombosis Associated with Viral Hepatitis.
J Clin Transl Hepatol. 2014 Dec;2(4):234-9. doi: 10.14218/JCTH.2014.00031. Epub 2014 Dec 15.
6
Hemostasis abnormalities in cirrhosis.
Curr Opin Hematol. 2015 Sep;22(5):406-12. doi: 10.1097/MOH.0000000000000164.
7
The Fibrinolytic Status in Liver Diseases.
Semin Thromb Hemost. 2015 Jul;41(5):474-80. doi: 10.1055/s-0035-1550437. Epub 2015 Jun 6.
9
Hepatic arterial vasodilation is independent of portal hypertension in early stages of cirrhosis.
PLoS One. 2015 Mar 20;10(3):e0121229. doi: 10.1371/journal.pone.0121229. eCollection 2015.
10
Factors associated with the platelet count in patients with chronic hepatitis C.
Thromb Res. 2015 May;135(5):823-8. doi: 10.1016/j.thromres.2015.02.010. Epub 2015 Feb 19.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验